Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CDK8 inhibitor

DRUG CLASS:

CDK8 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	RVU120 Sensitive: C3 – Early Trials RVU120 Sensitive : C3	RVU120 Sensitive: C3 – Early Trials RVU120 Sensitive : C3
DNMT3A mutation	Myelodysplastic Syndrome	DNMT3A mutation	Myelodysplastic Syndrome	RVU120 Sensitive: C4 – Case Studies RVU120 Sensitive : C4	RVU120 Sensitive: C4 – Case Studies RVU120 Sensitive : C4
DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	RVU120 Sensitive: C4 – Case Studies RVU120 Sensitive : C4	RVU120 Sensitive: C4 – Case Studies RVU120 Sensitive : C4
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib + Senexin B Sensitive: D – Preclinical palbociclib + Senexin B Sensitive : D	palbociclib + Senexin B Sensitive: D – Preclinical palbociclib + Senexin B Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib + SNX-631 Sensitive: D – Preclinical palbociclib + SNX-631 Sensitive : D	palbociclib + SNX-631 Sensitive: D – Preclinical palbociclib + SNX-631 Sensitive : D
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	CDK8 inhibitor Sensitive: D – Preclinical CDK8 inhibitor Sensitive : D	CDK8 inhibitor Sensitive: D – Preclinical CDK8 inhibitor Sensitive : D
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	RVU120 Sensitive: D – Preclinical RVU120 Sensitive : D	RVU120 Sensitive: D – Preclinical RVU120 Sensitive : D
PIK3CA mutation	Triple Negative Breast Cancer	PIK3CA mutation	Triple Negative Breast Cancer	everolimus + SNX-631 Sensitive: D – Preclinical everolimus + SNX-631 Sensitive : D	everolimus + SNX-631 Sensitive: D – Preclinical everolimus + SNX-631 Sensitive : D
PTEN mutation	Triple Negative Breast Cancer	PTEN mutation	Triple Negative Breast Cancer	everolimus + SNX-631 Sensitive: D – Preclinical everolimus + SNX-631 Sensitive : D	everolimus + SNX-631 Sensitive: D – Preclinical everolimus + SNX-631 Sensitive : D
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gilteritinib + RVU120 Sensitive: D – Preclinical gilteritinib + RVU120 Sensitive : D	gilteritinib + RVU120 Sensitive: D – Preclinical gilteritinib + RVU120 Sensitive : D
HR negative + EGFR amplification	Triple Negative Breast Cancer	HR negative + EGFR amplification	Triple Negative Breast Cancer	RVU120 Sensitive: D – Preclinical RVU120 Sensitive : D	RVU120 Sensitive: D – Preclinical RVU120 Sensitive : D